Trevi Therapeutics, Inc.
General ticker "TRVI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $779.2M (TTM average)
Trevi Therapeutics, Inc. follows the US Stock Market performance with the rate: 51.6%.
Estimated limits based on current volatility of 3.6%: low 13.91$, high 14.95$
Factors to consider:
- Total employees count: 26 (+4.0%) as of 2024
- Top business risk factors: Operational and conduct risks, Single product reliance, Regulatory and compliance, Labor/talent shortage/retention, Transition to commercialization
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [7.77$, 17.02$]
- 2026-12-31 to 2027-12-31 estimated range: [6.25$, 14.20$]
Financial Metrics affecting the TRVI estimates:
- Positive: with PPE of -39.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -2.29 <= 0.07
- Negative: negative Net income
- Negative: Investing cash flow per share per price, % of -5.12 <= -4.45
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating income (median)
- Negative: Shareholder equity ratio, % of 94.73 > 64.25
- Negative: negative Industry operating cash flow (median)
Short-term TRVI quotes
Long-term TRVI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $33.92MM | $51.52MM | $49.33MM |
| Operating Income | $-33.92MM | $-51.52MM | $-49.33MM |
| Non-Operating Income | $4.83MM | $3.58MM | $6.50MM |
| Interest Expense | $0.39MM | $0.00MM | $0.00MM |
| R&D Expense | $23.68MM | $39.38MM | $33.48MM |
| Income(Loss) | $-29.10MM | $-47.94MM | $-42.82MM |
| Taxes | $-0.03MM | $-0.03MM | $-0.06MM |
| Profit(Loss)* | $-29.07MM | $-47.91MM | $-42.76MM |
| Stockholders Equity | $82.55MM | $99.64MM | $183.24MM |
| Assets | $89.40MM | $110.90MM | $193.44MM |
| Operating Cash Flow | $-31.71MM | $-38.26MM | $-42.09MM |
| Capital expenditure | $0.14MM | $0.04MM | $0.01MM |
| Investing Cash Flow | $59.43MM | $-21.53MM | $-94.11MM |
| Financing Cash Flow | $-7.91MM | $61.48MM | $121.01MM |
| Earnings Per Share** | $-0.29 | $-0.47 | $-0.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.